Development of a Pediatric pVAD

Information

  • Research Project
  • 6833856
  • ApplicationId
    6833856
  • Core Project Number
    R43HL078077
  • Full Project Number
    1R43HL078077-01
  • Serial Number
    78077
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/1/2004 - 21 years ago
  • Project End Date
    12/31/2004 - 20 years ago
  • Program Officer Name
    BALDWIN, TIM
  • Budget Start Date
    7/1/2004 - 21 years ago
  • Budget End Date
    12/31/2004 - 20 years ago
  • Fiscal Year
    2004
  • Support Year
    1
  • Suffix
  • Award Notice Date
    5/10/2004 - 21 years ago
Organizations

Development of a Pediatric pVAD

[unreadable] DESCRIPTION (provided by applicant): [unreadable] In the United States, approximately 4,000 pediatric patients per year require a ventricular assist device (VAD) due to idiopathic cardiomyopathy or congenital heart defects. Despite this tremendous need, there is currently no specially designed VAD commercially available in the US for pediatric use. The ultimate goal of this project is to develop a percutaneous VAD (pVAD) for pediatric patients ranging from 3.5 kg to 50 kg based on our existing adult pVAD system. The proposed system is intended to deliver support of up to 50% of the patient's normal cardiac output. Due to the wide range of patient sizes, and consequent wide variety of support levels needed, the served patient population has been divided into six segments based on patient's body size. For each patient segment, cannula of proper size will be developed for device placement. A pediatric pump will be designed based on the existing adult blood pump. Controller will be redesigned for pediatric application. Feasibility prototypes will be manufactured and tested under simulated clinical use conditions to demonstrate that the proposed design can deliver the required support for each patient segment. Hemolysis testing will be conducted to demonstrate that the proposed design does not cause excessive blood damage. Phase II study includes optimization of the proposed design and animal testing. After successful completion of Phase I and II, clinical trial and commercialization of the proposed device will follow. The proposed system is simple and low cost. Because it is inserted percutaneously, cardiac assistance can be provided quickly and with minimum invasiveness, subsequently minimizing potential complications and promoting quicker recovery. Successful commercialization of this device will provide a new tool for use in pediatric cardiology and surgery, and will help save children's lives. [unreadable] [unreadable]

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    105074
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:105074\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CARDIACASSIST, INC.
  • Organization Department
  • Organization DUNS
    948683941
  • Organization City
    PITTSBURGH
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    152382906
  • Organization District
    UNITED STATES